Early treatment offers chance at medication-free remission for pediatric HIV patients

An unexpectedly high percentage of children, who were born with HIV and started treatment within 48 hours of life, exhibit biomarkers by 2 years of age that may make them eligible to test for medication-free remission, according to a multinational study published in Lancet HIV.

Not Disclosed Neurodegeneration by Eli Lilly and Co for Neurodegenerative Diseases: Likelihood of Approval

Not Disclosed Neurodegeneration is under clinical development by Eli Lilly and Co and currently in Phase I for Neurodegenerative Diseases.

February 20, 2024

Lilly reaches $2.4 million settlement with EEOC over age discrimination lawsuit

Eli Lilly agreed to pay $2.4 million as part of a settlement with the U.S. Equal Employment Opportunity Commission, which had filed a lawsuit accusing

June 27, 2023

Enveric’s EB-003 selected as lead drug for mental health disorders

Share this article EB-003 was selected based on data assessments indicating its potential to offer a first-in-class approach to treat hard-to-treat mental health conditions. Credit:

December 29, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.